Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

Blood

Volumn 98, Issue 10, 2001, Pages 2930-2934

  Weihrauch, Martin R ^a,b,c,d   Re, Daniel ^a,b,c   Scheidhauer, Klemens ^a,b,c   Ansén, Sascha ^a,b,c   Dietlein, Markus ^a,b,c   Bischoff, Stefanie ^a,b,c   Bohlen, Heribert ^a,b,c   Wolf, Jürgen ^a,b,c   Schicha, Harald ^a,b,c   Diehl, Volker ^a,b,c   Tesch, Hans ^a,b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Pluriomics BV   (Germany)

^c SCHWARZWALD BAAR KLINIKUM   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CHEMOTHERAPY; CLINICAL ARTICLE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FIBROSIS; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMAGING; MALE; MEDIASTINUM DISEASE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOTHERAPY; RELAPSE; REMISSION; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 19244367762     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.2930     Document Type: Article

References (32)

1. Sieber M, Engert A, Diehl V. Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol. 2000;11(suppl 1):81-85.
2. Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol. 1998;9:289-295.
3. Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol. 1988;6:940-946.
4. Israel O, Front D, Lam M, et al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer. 1988;61:2439-2443.
5. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931-933.
6. Sarrazin R, Dyon JF. Mediastinoscopy. Rev Mal Respir. 1992;9:99-110.
7. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 1997;203:795-800.
8. de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8(suppl 1):57-60.
9. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 1997;38:343-348.
10. Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma. 1999;34:545-551.
11. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica. 2001;86:266-273.
12. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol. 2000;11:1273-1279.
13. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25:721-728.
14. Bangerter M, Moog F, Buchmann I, et al. Wholebody 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol. 1998;9:1117-1122.
15. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 1999;20:13-20.
16. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
17. Nyman R, Forsgren G, Glimelius B. Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging. Acta Radiol. 1996;37:323-326.
18. Nyman RS, Rehn SM, Glimelius BL, et al. Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. Radiology. 1989;170:435-440.
19. Glazer HS, Lee JK, Levitt RG, et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology. 1985;156:721-726.
20. Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol. 1993;11:2273-2278.
21. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med. 2000;27:1564-1578.
22. Kostakoglu L, Yeh SD, Portlock C, et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med. 1992;33:345-350.
23. Setoain FJ, Pons F, Herranz R, et al. 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. Nucl Med Commun. 1997;18:405-411.
24. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28:288-292.
25. Mainolfi C, Maurea S, Varrella P, et al. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment]. Radiol Med (Torino). 1998;95:98-104.
26. Cremerius U, Fabry U, Kroll U, et al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma-results of a retrospective study in 72 patients. Nuklearmedizin. 1999;38:24- 30.
27. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433.
28. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055-1063.
29. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10:1181-1184.
30. Shin MS, Ho KJ. Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin's disease: an immunologic rebound phenomenon? Cancer. 1983;51:30-33.
31. Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J, False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med. 1997;38:888-890.
32. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 2001;12:29-37.